Skip to main content

rentosertib

Insilico Doses First Patient in Phase III Trial of AI-Discovered IPF Drug

Insilico Doses First Patient in Phase III Trial of AI-Discovered IPF Drug

Cambridge – – September 15, 2026 -- Insilico Medicine (HKEX: 3696) has dosed the first patient in GENESIS-IPF-3, a Phase III trial of Rentosertib, marking what the company calls the world's first late-stage clinical study of a drug candidate discovered and developed using generative AI.

Peking and Shanghai hospitals simultaneously enroll first patients

The dosing occurred at Peking Union Medical College Hospital, with Shanghai Pulmonary Hospital enrolling its own first patient on the same day. Professor Zuojun Xu of Peking Union Medical College Hospital serves as Leading Principal Investigator, with Academician Nanshan Zhong and President Chang Chen of Shanghai Pulmonary Hospital as Co-Leading PIs.

Six Proteomic Clocks Confirm Insilico's AI Drug Reverses Biological Age

Cambridge, Massachusetts – September 09, 2026 -- Insilico Medicine has published data in Nature Biotechnology showing that its AI-designed idiopathic pulmonary fibrosis (IPF) candidate rentosertib reversed predicted biological age by up to six years in some patients, based on six independently developed proteomic aging clocks.